Overexpression of Nucleolin is a Potential Prognostic Marker in Endometrial Carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Di Tucci C, Capone C, Galati G, et al. Immunotherapy in endometrial cancer: new scenarios on the horizon. J Gynecol Oncol. 2019;30(3):e46. doi:10.3802/jgo.2019.30.e4630887763
   PubMed Web of Science ®Google Scholar
• Oaknin A, Leon-Castillo A, Lorusso D. Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives. Curr Opin Oncol. 2020;32(5):471–480. doi:10.1097/CCO.000000000000065832740093
   PubMed Web of Science ®Google Scholar
• Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017:2017. doi:10.1200/PO.17.00073
   Web of Science ®Google Scholar
• Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110(4):354–361. doi:10.1093/jnci/djx21429045681
   PubMedGoogle Scholar
• Banno K, Kisu I, Yanokura M, et al. Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. Epigenomics. 2012;4(2):147–162. doi:10.2217/epi.12.1322449187
   PubMed Web of Science ®Google Scholar
• Berger CM, Gaume X, Bouvet P. The roles of nucleolin subcellular localization in cancer. Biochimie. 2015;113:78–85. doi:10.1016/j.biochi.2015.03.02325866190
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhao G, Zhang S, et al. AS1411-induced growth inhibition of glioma cells by up-regulation of p53 and down-regulation of Bcl-2 and Akt1 via nucleolin. PLoS One. 2016;11(12):e0167094. doi:10.1371/journal.pone.016709427907160
   PubMed Web of Science ®Google Scholar
• Subramanian N, Srimany A, Kanwar JR, et al. Nucleolin-aptamer therapy in retinoblastoma: molecular changes and mass spectrometry-based imaging. Mol Ther Nucleic Acids. 2016;5(8):e358. doi:10.1038/mtna.2016.7027574784
   PubMedGoogle Scholar
• Bose S, Tholanikunnel TE, Reuben A, Tholanikunnel BG, Spicer EK. Regulation of nucleolin expression by miR-194, miR-206, and HuR. Mol Cell Biochem. 2016;417(1–2):141–153. doi:10.1007/s11010-016-2721-227221739
   PubMed Web of Science ®Google Scholar
• Xu J-Y, Lu S, Xu X-Y, et al. Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcs. Tumour Biol. 2016;37(8):10349–10356. doi:10.1007/s13277-016-4920-626846099
   PubMedGoogle Scholar
• Orrick LR, Olson MO, Busch H. Comparison of nucleolar proteins of normal rat liver and Novikoff hepatoma ascites cells by two-dimensional polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A. 1973;70(5):1316–1320. doi:10.1073/pnas.70.5.13164351171
   PubMed Web of Science ®Google Scholar
• Nguyen Van Long F, Lardy-Cleaud A, Bray S. Druggable nucleolin identifies breast tumours associated with poor prognosis that exhibit different biological processes. Cancers (Basel). 2018;10(10):390. doi:10.3390/cancers10100390
   PubMed Web of Science ®Google Scholar
• Qiu W, Zhou F, Zhang Q, et al. Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer. APMIS. 2013;121(10):919–925. doi:10.1111/apm.1213123763304
   PubMed Web of Science ®Google Scholar
• Guo X, Xiong L, Yu L, et al. Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Diagn Pathol. 2014;9(1):175. doi:10.1186/s13000-014-0175-y25230759
   PubMed Web of Science ®Google Scholar
• Marcel V, Catez F, Berger CM, et al. Expression profiling of ribosome biogenesis factors reveals nucleolin as a novel potential marker to predict outcome in AML patients. PLoS One. 2017;12(1):e0170160. doi:10.1371/journal.pone.017016028103300
   PubMed Web of Science ®Google Scholar
• Zhao H, Huang Y, Xue C, et al. Prognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically resected non-small cell lung cancer. PLoS One. 2013;8(1):e54674. doi:10.1371/journal.pone.005467423382938
   PubMed Web of Science ®Google Scholar
• Gilles ME, Maione F, Cossutta M, et al. Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature. Cancer Res. 2016;76(24):7181–7193. doi:10.1158/0008-5472.CAN-16-030027754848
   PubMed Web of Science ®Google Scholar
• Ugrinova I, Monier K, Ivaldi C, et al. Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication. BMC Mol Biol. 2007;8(1):66. doi:10.1186/1471-2199-8-6617692122
   PubMed Web of Science ®Google Scholar
• Xu JY, Lu S, Xu XY, et al. Knocking down nucleolin expression enhances the radiosensitivity of non-small cell lung cancer by influencing DNA-PKcs activity. Asian Pac J Cancer Prev. 2015;16(8):3301–3306. doi:10.7314/APJCP.2015.16.8.330125921135
   PubMedGoogle Scholar
• Benedetti E, Antonosante A, d’Angelo M, et al. Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model. Oncotarget. 2015;6(39):42091–42104. doi:10.18632/oncotarget.599026540346
   PubMedGoogle Scholar
• Qian B, Yao Y, Liu Y, Yan M, Huang Y, Chen Y. Nucleolin identified by comparative mass spectra analysis is a potential marker for invasive progression of hepatocellular carcinoma. Mol Med Rep. 2014;10(3):1489–1494. doi:10.3892/mmr.2014.232124927373
   PubMed Web of Science ®Google Scholar
• Li Y, Tang Y, Ye L, et al. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 2003;129(1):43–51. doi:10.1007/s00432-002-0396-412618900
   PubMed Web of Science ®Google Scholar
• Choi WT, Yang Y, Xu Y, An J. Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis. Curr Top Med Chem. 2014;14(13):1574–1589. doi:10.2174/156802661466614082714354125159167
   PubMed Web of Science ®Google Scholar
• Niu H, Yang X, Xu Z, Du T, Wang R. Cell surface nucleolin interacts with CXCR4 receptor via the 212 c-terminal portion. Tumour Biol. 2015;36(2):1099–1104. doi:10.1007/s13277-014-2734-y25326811
   PubMedGoogle Scholar
• Destouches D, El Khoury D, Hamma-Kourbali Y, et al. Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS One. 2008;3(6):e2518. doi:10.1371/journal.pone.000251818560571
   PubMed Web of Science ®Google Scholar
• Krust B, El Khoury D, Soundaramourty C, Nondier I, Hovanessian AG. Suppression of tumorigenicity of rhabdoid tumor derived G401 cells by the multivalent HB-19 pseudopeptide that targets surface nucleolin. Biochimie. 2011;93(3):426–433. doi:10.1016/j.biochi.2010.10.01521040752
   PubMed Web of Science ®Google Scholar
• Destouches D, Page N, Hamma-Kourbali Y, et al. A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins. Cancer Res. 2011;71(9):3296–3305. doi:10.1158/0008-5472.CAN-10-345921415166
   PubMed Web of Science ®Google Scholar
• D’Avino C, Palmieri D, Braddom A, et al. A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy. Oncotarget. 2016;7(52):87016–87030. doi:10.18632/oncotarget.1352227894092
   PubMedGoogle Scholar
• Palmieri D, Richmond T, Piovan C, et al. Human anti-nucleolin recombinant immunoagent for cancer therapy. Proc Natl Acad Sci U S A. 2015;112(30):9418–9423. doi:10.1073/pnas.150708711226170308
   PubMed Web of Science ®Google Scholar
• Koutsioumpa M, Papadimitriou E. Cell surface nucleolin as a target for anti-cancer therapies. Recent Pat Anticancer Drug Discov. 2014;9(2):137–152. doi:10.2174/157489280866613111909595324251811
   PubMed Web of Science ®Google Scholar
• Tajrishi MM, Tuteja R, Nucleolin: TN. The most abundant multifunctional phosphoprotein of nucleolus. Commun Integr Biol. 2011;4(3):267–275. doi:10.4161/cib.4.3.1488421980556
   PubMedGoogle Scholar
• Wise JF, Berkova Z, Mathur R, et al. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood. 2013;121(23):4729–4739. doi:10.1182/blood-2012-12-47109423599269
   PubMed Web of Science ®Google Scholar
• Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 1989;56(3):379–390. doi:10.1016/0092-8674(89)90241-92914325
   PubMed Web of Science ®Google Scholar
• Sengupta TK, Bandyopadhyay S, Fernandes DJ, Spicer EK. Identification of nucleolin as an AU-rich element binding protein involved in bcl-2 mRNA stabilization. J Biol Chem. 2004;279(12):10855–10863. doi:10.1074/jbc.M30911120014679209
   PubMed Web of Science ®Google Scholar
• Otake Y, Sengupta TK, Bandyopadhyay S, Spicer EK, Fernandes DJ. Retinoid-induced apoptosis in HL-60 cells is associated with nucleolin down-regulation and destabilization of Bcl-2 mRNA. Mol Pharmacol. 2005;67(1):319–326. doi:10.1124/mol.104.00608015492114
   PubMed Web of Science ®Google Scholar
• Otake Y, Soundararajan S, Sengupta TK, et al. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood. 2007;109(7):3069–3075. doi:10.1182/blood-2006-08-04325717179226
   PubMed Web of Science ®Google Scholar
• Chen J, Guo K, Kastan MB. Interactions of nucleolin and ribosomal protein L26 (RPL26) in translational control of human p53 mRNA. J Biol Chem. 2012;287(20):16467–16476. doi:10.1074/jbc.M112.34927422433872
   PubMed Web of Science ®Google Scholar
• Abdelmohsen K, Tominaga K, Lee EK, et al. Enhanced translation by nucleolin via G-rich elements in coding and non-coding regions of target mRNAs. Nucleic Acids Res. 2011;39(19):8513–8530. doi:10.1093/nar/gkr48821737422
   PubMed Web of Science ®Google Scholar